Â鶹´«Ã½ÊÓƵÍøÕ¾

Primary Objective

The primary objective of the CONVINCE study is to compare high-dose haemodiafiltrationÌýwith high-flux haemodialysisÌýtreatment in terms of all-cause mortality.

Primary Endpoint

The primary endpoint is defined as difference in rate for all-cause mortality.

Secondary Objectives

1. Compare high-dose high-dose haemodiafiltration with high-flux haemodialysis treatment in terms of cause specific morbidity and mortality.
2. Assess patient reported outcome measures and patient reported experience measures to capture and patient perspectives and compare between high-dose haemodiafiltration with high-flux haemodialysis treatment.

Ìý3. Assess cost effectiveness of high-dose haemodiafiltration compared to high-flux haemodialysis.

Secondary Endpoints

The secondary endpoints are:

1. Cause specific mortality (at least cardiovascular and non-cardiovascular death; others with high frequency may be added);
2. Non-fatal and fatal cardiovascular events;
3. Hospitalisation for infection-related conditions;
4. All cause hospitalisations;
5. PREMS and PROMS;

6.Ìý Cost effectiveness.

Ìý